Bain Capital Life Sciences Opportunities III, LP 13D and 13G filings for Kyverna Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 4:30 pm Sale | 2025-12-31 | 13G | KYVERNA THERAPEUTICS INC KYTX | Bain Capital Life Sciences Opportunities III, LP | 3,110,000 5.400% | -53,868 (-1.70%) | Filing |
| 2024-02-14 5:20 pm Purchase | 2024-02-07 | 13G | KYVERNA THERAPEUTICS INC KYTX | Bain Capital Life Sciences Opportunities III, LP | 3,163,868 7.400% | 3,163,868 (New Position) | Filing |